Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Szulkin, Adam ^a   Ötvös, Rita ^b   Hillerdal, Carl Olof ^a   Celep, Aytekin ^a   Yousef Fadhel, Eviane ^a   Skribek, Henriette ^b   Hjerpe, Anders ^a   Székely, László ^b   Dobra, Katalin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chemotherapy; Cytotoxic drugs; ERCC1 and Individualized treatment; Ex vivo chemosensitivity; Malignant mesothelioma; Pleural effusions; Primary cells; RRM1

Indexed keywords

ASPARAGINASE; BORTEZOMIB; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUDARABINE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PREDNISOLONE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE LARGE SUBUNIT M1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER SURVIVAL; CELL ISOLATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; SURVIVAL TIME; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; PATHOLOGY; PLEURAL EFFUSION, MALIGNANT; SURVIVAL; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84910022357     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-709     Document Type: Article

References (45)

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271. 1038078, 13782506.
2. Suzuki Y. Pathology of human malignant mesothelioma-preliminary analysis of 1,517 mesothelioma cases. Ind Health 2001, 39(2):183-185. 10.2486/indhealth.39.183, 11341549.
3. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988, 6(1):147-153.
4. Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. Am Fam Physician 2006, 73(7):1211-1220.
5. Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, Kucukoner M, Kaplan MA, Celik Y, Senyigit A. Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci 2013, 17(1):19-24.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Paoleti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644. 10.1200/JCO.2003.11.136, 12860938.
7. Nowak AK. Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg 2012, 1(4):508-515. 3741799, 23977545.
8. Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Fennell DA. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer 2012, 48(16):2983-2992. 10.1016/j.ejca.2012.05.018, 22704893.
9. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23. 10.1016/j.ctrv.2006.09.006, 1855222, 17084534.
10. Wang J, Lohman GJ, Stubbe J. Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci U S A 2007, 104(36):14324-14329. 10.1073/pnas.0706803104, 1964847, 17726094.
11. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Soria JC. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991. 10.1056/NEJMoa060570, 16957145.
12. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27(34):5808-5815. 10.1200/JCO.2009.21.9766, 2793001, 19884554.
13. Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 2012, 7(1):249-256. 10.1097/JTO.0b013e318233d6a9, 22031231.
14. Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW, Christoph DC. ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer 2013, 14(5):558-567. e553, 10.1016/j.cllc.2013.04.013, 23810210.
15. Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2012, 70(5):743-754. 10.1007/s00280-012-1965-0, 22960937.
16. Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, Hjerpe A, Dobra K. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One 2013, 8(6):e65903. 10.1371/journal.pone.0065903, 3688685, 23840376.
17. Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time?. J Clin Oncol 2013, 31(8):1050-1060. 10.1200/JCO.2012.43.0900, 23401439.
18. Mundt F, Nilsonne G, Arslan S, Csuros K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 2013, 8(8):e72030. 10.1371/journal.pone.0072030, 3749097, 23991032.
19. Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers 2013, 35(2):119-127. 3774973, 24167356.
20. Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 2013, 82(3):491-498. 10.1016/j.lungcan.2013.09.016, 24161718.
21. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001, 92(5):1224-1230. 10.1002/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U, 11571736.
22. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology 2002, 12(3):37R-42R. 10.1093/glycob/12.3.37R, 11971857.
23. Liu Z, Dobra K, Hauzenberger D, Klominek J. Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells. Anticancer Res 2004, 24(2B):599-603.
24. Asplund T, Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res 1994, 54(16):4516-4523.
25. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008, 44(1):46-53. 10.1016/j.ejca.2007.08.028, 2265108, 17945478.
26. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992, 50(3):373-381. 10.1002/ijc.2910500308, 1735605.
27. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004, 10(12 Pt 1):3937-3942.
28. Hjerpe A. Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids. Clin Chem 1986, 32(6):952-956.
29. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005, 32(3):160-166. 10.1002/dc.20202, 15690331.
30. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer 2010, 68(1):39-43. 10.1016/j.lungcan.2009.05.004, 19523712.
31. Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013, 45(1):44-48. 10.1097/PAT.0b013e32835bc848, 23222247.
32. Klominek J, Robert KH, Hjerpe A, Wickstrom B, Gahrton G. Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res 1989, 49(21):6118-6122.
33. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992, 51(2):296-301. 10.1002/ijc.2910510220, 1373705.
34. Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, Klockars M, Jantunen K, Gerwin BI, Harris CC, Tuomi T, Vanhala E, Mattson K, Linnainmaa K. Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 1990, 11(4):673-681. 10.1093/carcin/11.4.673, 2323006.
35. Otvos R, Skribek H, Kis LL, Gloghini A, Markasz L, Flaberg E, Eksborg S, Konya J, Gergely L, Carbone A, Szekely L. Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. BMC Cancer 2011, 11:441. 10.1186/1471-2407-11-441, 3224241, 21992895.
36. Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, Masszi T, Kozma A, Adam E, Miseta A, Szekely L. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol 2010, 38(12):1219-1230. 10.1016/j.exphem.2010.09.001, 20837094.
37. Flaberg E, Sabelstrom P, Strandh C, Szekely L. Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging 2008, 8:13. 10.1186/1471-2342-8-13, 2515298, 18627634.
38. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008, 5(3):136-147. 10.1038/ncponc1039, 18227828.
39. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006, 1(6):591-601. 10.1097/01243894-200607000-00017, 17409924.
40. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008, 9(2-3):171-179. 2782121, 18770046.
41. Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlof AK, Fernandes AP, Bjornstedt M, Dobra K. Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res 2009, 28:92. 10.1186/1756-9966-28-92, 2711967, 19563663.
42. Vilmar AC, Santoni-Rugiu E, Sorensen JB. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol 2013, 24(2):309-314. 10.1093/annonc/mds335, 23038758.
43. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006, 24(9):1443-1448. 10.1200/JCO.2005.04.3190, 16549838.
44. Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010, 11(1):30-35. 10.3816/CLC.2010.n.005, 20085865.
45. Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008, 3(11):1325-1331. 10.1097/JTO.0b013e31818b174d, 18978569.